Targets › GFAP
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Jul 2034.
GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. (UniProt, P14136)
Open in Phaseline: the race on GFAP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals | zilganersen (ION373) Antisense oligonucleotide targeting GFAP mRNA | GFAP | Phase 3 | Alexander Disease | Jul 2034 |
Alexander Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.